Transforming refractory cancer treatment-induced thrombocytopenia management: a real-world retrospective cohort study of fixed-dose romiplostim

Background Treatment options for refractory cancer therapy-induced thrombocytopenia (R-CTIT) are limited. This real-world retrospective cohort study evaluated the effectiveness and safety of fixed-dose romiplostim in patients with R-CTIT. Methods In this retrospective analysis, 28 patients with R-CTIT received romiplostim (250 μg/week) at our center (2023–2024). Outcomes included time to response, platelet increase, bleeding score, transfusion independence, and safety. Results Median time to platelet response was 7 days. By week 3, platelet counts rose from 19 × 10 9 /L to 136 × 10 9 /L ( P < 0.001), with an objective response rate (ORR) of 92.9% (26/28; 75% complete response). At week 8, responses were sustained (ORR 92.9%; platelets 108 × 10 9 /L, P < 0.001). Bleeding scores improved; 93.3% achieved platelet transfusion independence. Hemoglobin increased (90 g/L to 112 g/L, P = 0.029), with a trend toward higher neutrophils. Twenty responders resumed anticancer therapy. After romiplostim discontinuation (n = 7), 71.4% experienced recurrent grade IV thrombocytopenia. Three patients (10.7%) developed deep vein thrombosis. Conclusion Fixed-dose romiplostim (250 μg/week) induces rapid and durable platelet responses, improves bleeding and hematologic parameters, and facilitates continued anticancer therapy in R-CTIT in this real-world retrospective cohort. Thrombocytopenia commonly recurs after stopping, and thrombotic risk warrants monitoring. Prospective studies with larger samples and a control group are needed to confirm these findings.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-19
DOI
https://doi.org/10.3389/fphar.2026.1963885
Primary Topic
Platelet Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Transforming refractory cancer treatment-induced thrombocytopenia management: a real-world retrospective cohort study of fixed-dose romiplostim

Zhenxing Zhu, Ruiqi Wang, Wenlong Zhang
Frontiers in Pharmacology
Platelet Disorders and Treatments
article

Transforming refractory cancer treatment-induced thrombocytopenia management: a real-world retrospective cohort study of fixed-dose romiplostim

Zhenxing Zhu, Ruiqi Wang, Wenlong Zhang
article en

Abstract

Background Treatment options for refractory cancer therapy-induced thrombocytopenia (R-CTIT) are limited. This real-world retrospective cohort study evaluated the effectiveness and safety of fixed-dose romiplostim in patients with R-CTIT. Methods In this retrospective analysis, 28 patients with R-CTIT received romiplostim (250 μg/week) at our center (2023–2024). Outcomes included time to response, platelet increase, bleeding score, transfusion independence, and safety. Results Median time to platelet response was 7 days. By week 3, platelet counts rose from 19 × 10 9 /L to 136 × 10 9 /L ( P < 0.001), with an objective response rate (ORR) of 92.9% (26/28; 75% complete response). At week 8, responses were sustained (ORR 92.9%; platelets 108 × 10 9 /L, P < 0.001). Bleeding scores improved; 93.3% achieved platelet transfusion independence. Hemoglobin increased (90 g/L to 112 g/L, P = 0.029), with a trend toward higher neutrophils. Twenty responders resumed anticancer therapy. After romiplostim discontinuation (n = 7), 71.4% experienced recurrent grade IV thrombocytopenia. Three patients (10.7%) developed deep vein thrombosis. Conclusion Fixed-dose romiplostim (250 μg/week) induces rapid and durable platelet responses, improves bleeding and hematologic parameters, and facilitates continued anticancer therapy in R-CTIT in this real-world retrospective cohort. Thrombocytopenia commonly recurs after stopping, and thrombotic risk warrants monitoring. Prospective studies with larger samples and a control group are needed to confirm these findings.

Frontiers in PharmacologyVol. 17
Jilin University (CN)
Platelet Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon